Walleye Capital’s Ascendis Pharma A/S ASND Stock Holding History

Walleye Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$846K	Sell	3,700 -900	-20%	-$202K	﹤0.01%	2228
2025 Q4	$981K	Buy	4,600 +3,500	+318%	+$723K	﹤0.01%	2447
2025 Q3	$219K	Buy	1,100 +400	+57%	+$74.6K	﹤0.01%	3260
2025 Q2	$121K	Buy	+700	New	+$114K	﹤0.01%	3681
2024 Q4	–	Sell	-900	Closed	-$134K	–	4829
2024 Q3	$134K	Sell	900 -1,100	-55%	-$149K	﹤0.01%	4256
2024 Q2	$273K	Sell	2,000 -1,000	-33%	-$136K	﹤0.01%	4059
2024 Q1	$454K	Buy	3,000 +2,400	+400%	+$343K	﹤0.01%	3279
2023 Q4	$75.6K	Sell	600 -1,300	-68%	-$130K	﹤0.01%	4166
2023 Q3	$178K	Sell	1,900 -700	-27%	-$65.5K	﹤0.01%	3630
2023 Q2	$232K	Sell	2,600 -3,000	-54%	-$261K	﹤0.01%	2989
2023 Q1	$600K	Sell	5,600 -900	-14%	-$103K	0.01%	1561
2022 Q4	$794K	Buy	6,500 +3,200	+97%	+$372K	0.01%	1140
2022 Q3	$341K	Buy	+3,300	New	+$313K	0.01%	1741

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Walleye Capital's ASND Position: Q1 2026 in Review

Walleye Capital reduced its Ascendis Pharma A/S (ASND) stake by 94% in Q1 2026, selling an estimated $132K and leaving 37 shares worth $8.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4169.

Walleye Capital first reported a position in ASND in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.97M in Q2 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Walleye Capital held 37 shares of Ascendis Pharma A/S worth $8.46K as of Q1 2026.
Walleye Capital sold 591 Ascendis Pharma A/S shares in Q1 2026, an estimated $132K.
Ascendis Pharma A/S made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4169 holding.
Walleye Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and has held it in 8 quarters since.
Walleye Capital's Ascendis Pharma A/S position peaked at $6.97M in Q2 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.